Baxter JD, Rousseau GG, eds. Glucocorticoid Hormone Action. New York: Springer-Verlag; 1979.
Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985; 318:635-41.
Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol. 1993; 7:4-11.
Ku Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59 kd immunophilin with the glucocorticoid receptor complex. Science. 1992; 256:1315-8.
Picard D, Khursheed B, Garabedian MJ, Fortin MG, Lindon S, Yamamoto K. Reduced levels of HSP 90 compromise steroid receptor action in vivo. Nature. 1990; 348:166-8.
Tsai SY, Carlstedt-Duke J, Weigel NL, Dahlman K, Gustafsson JA, Tsai MJ, et al. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell. 1988; 55:361-9.
Picard D, Yamamoto KR. Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J. 1987; 6:3333-40.
Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Siegler PB. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature. 1991; 352:497-505.
Drouin J, Sun YL, Tremblay S, Lavender P, Schmidt TJ, deLean A, et al. Homodimer formation is rate-limiting for high affinity DNA binding by glucocorticoid receptor. Mol Endocrinol. 1992; 6:1299-309.
Sharp PA. IIB or not IIB. Nature. 1991; 351:16-7.
Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR. Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science. 1992; 258:1598-604.
Simons SS Jr, Oshima H, Szapary D. Higher level of control: modulation of steroid-regulated gene transcription. Mol Endocrinol. 1992; 6:995-1002.
Schule R, Muller M, Otsuka-Murakami H, Renkawitz R. Cooperativity of the glucocorticoid receptor and the CACCC-box binding factor. Nature. 1988; 332:87-90.
Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR. Hormone-mediated repression of transcription: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev. 1988; 2:1144-54.
Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science. 1990; 249:1266-72.
Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990; 62:1205-15.
Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990; 62:1217-26.
Jonat C, Rahmsdorf HJ, Par KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990; 62: 1189-204.
Akerblom IW, Slater ER, Beato M, Baxter JD, Mellon PL. Negative regulation by glucocorticoid through interference with a cAMP responsive enhancer. Science. 1988; 241:350-3.
Kern JA, Laumb RT, Reed JC, Daniel RP, Nowell PC. Dexamathasone inhibition of interleukin-1 production by human monocytes: post transcriptional mechanisms. J Clin Invest. 1988; 81:237-44.
Boggaram V, Smith ME, Mendelson CR. Posttranscriptional regulation of surfactant protein: a messenger RNA in human fetal lung in vitro by glucocorticoids. Mol Endocrinol. 1991; 5:414-23.
Vesely DL. On the mechanism of action of adrenocortical steroids: cortisol and aldosterone enhance guanylate cyclase activity. J Pharmacol Exp Ther. 1980; 214:561-6.
Kerr DS, Campbell LW, Thibault O, Landfield PW. Hippocampal glucocorticoid receptor activation enhances voltage-dependent Ca++ conductances: relevance to brain aging. Proc Natl Acad Sci USA. 1992; 89:8527-31.
Manolios N, Geczy C, Schreiber L. Lymphocyte migration in health and inflammatory rheumatic diseases. Semin Arthritis Rheum. 1991; 209:339-52.
Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today. 1992; 13:93-100.
Shimizu YH, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunol Today. 1992; 13:106-13.
Sternberg EM, Wilder RL. Corticosteroids. In: McCarty DJ, Koopman WJ, eds. Arthritis and Allied Conditions. Philadelphia: Lea & Febiger; 1993:665-82.
Klein A, Buskila D, Gladman D, Bruser B, Malkin A. Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 1990; 17:30-3.
Podgorski MR, Goulding NJ, Hall ND, Flower RJ, Maddison PJ. Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis. J Rheumatol. 1992; 19:1668-71.
Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med. 1992; 117:854-66.
Wilder RL, Sternberg EM. Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions. Curr Opin Rheumatol. 1990; 2:436-40.
Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intracellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992; 89:9991-5.
Barton GJ, Newman RH, Freemont PS, Crumpton MF. Amino acid sequence analysis of the annexin super-gene family of proteins. Eur J Biochem. 1991; 198:749-60.
Bailey JM. New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors. 1991; 3:97-102.
Goulding NJ, Guyre PM. Regulation of inflammation by lipocortin 1. Immunol Today. 1992; 13:295-7.
Mukherjee AB, Cordella-Miele E, Miele L. Regulation of extracellular phospholipase A2 activity: implications for inflammatory diseases. DNA Cell Biol. 1992; 11:233-43.
Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992; 89:7384-8.
Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A. 1992; 89:3917-21.
O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A. 1992; 89:4888-92.
Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992; 89:97-108.
Fauci AS, Dale DC. The effects of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest. 1974; 53:240-6.
Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976; 84:304-15.
Galili N, Galili U, Klein E, Rosenthal L, Nordenskjold B. Human T lymphocytes become glucocorticoid-sensitive upon immune activation. Cell Immunol. 1980; 50:440-4.
Nieto MA, Gonzalez A, Gambon F, Diaz-Espada F, Lopez-Rivas A. Apoptosis in human thymocytes after treatment with glucocorticoids. Clin Exp Immunol. 1992; 88:341-4.
Boumpas DT, Older SA, Anastassiou ED, Tsokos GC, Nelson D, Balow JE. Dexamethasone inhibits human IL-2 but not IL-2R gene expression in vitro at the level of nuclear transcription. J Clin Invest. 1991; 87:1739-47.
Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT. Negative transcriptional regulation of the human interleukin-2 gene by glucocorticoids through interference with nuclear factors AP-1 and NF-AT. J Clin Invest. 1993; 91:1481-9.
Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med. 1992; 175:637-46.
Paliogianni F, Ahuja SS, Balow JP, Balow JE, Boumpas DT. Novel mechanism for inhibition of T cells by glucocorticoids (GC): GC modulate signal transduction through IL-2 receptor. J Immunol. 1993; 151:4081-9.
Arya SK, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and -interferon messenger RNA. J Immunol. 1984; 133:273-6.
Wu CY, Fargeas C, Nakajima T, Delespesse G. Glucocorticoids suppress the production of interleukin 4 by human lymphocytes. Eur J Immunol. 1991; 21:2645-7.
Boumpas DT, Paliogianni F, Anastassiou ED, Balow JE. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol. 1991; 9:413-23.
Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-. J Immunol. 1991; 146:3523-7.
Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS. Effects of in vitro corticosteroids on B cell activation, proliferation and differentiation. J Clin Invest. 1985; 75:754-6.
Butler WT, Rossen RD. Effects of corticosteroids on immunity in man: decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest. 1973; 52:2629-40.
Thorn GW. Clinical considerations in the use of corticosteroids. N Engl J Med. 1966; 274:775-81.
David DS, Grieco MH, Cushman P Jr. Adrenal glucocorticoids after twenty years: a review of their clinically relevant consequences. J Chron Dis. 1970; 22:637-711.
Melby JC. Systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann Intern Med. 1974; 81:505-12.
Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976; 55: 39-65.
Lewis GP, Jusko WJ, Burke CW, Graves L, Boston Collaborative Drug Surveillance Program. Prednisone side-effects and serum protein levels: a collaborative study. Lancet. 1971; 2:778-80.
Kimberly RP. Treatment. Corticosteroids and anti-inflammatory drugs. Rheum Dis Clin North Am. 1988; 14:203-21.
Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med. 1979; 66: 910-4.
Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992; 326:226-30.
Baxter JD. The effects of glucocorticoid therapy. Hospital Pract. 1992; 27:111-34.
Napolitano LM, Chernow B. Guidelines for corticosteroid use in anesthetic and surgical stress. Int Anesthesiol Clin. 1988; 26:226-32.
Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effect of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977; 63:200-7.
Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm. 1981; 9:389-417.
Dale DC, Fauci AS, Wolff SM. Alternate-day prednisone: leukocyte kinetics and susceptibility to infections. N Engl J Med. 1974; 291: 1154-8.
Austin HA III, Antonovych TT, MacKay K, Boumpas DT, Balow JE. Membranous nephropathy. Ann Intern Med. 1992; 116:672-82.
Fauci AS, Leavitt RY. Systemic vasculitis. In: Lichtenstein LM, Fauci AS,eds. Current Therapy in Allergy, Immunology and Rheumatology-3. St. Louis: Mosby-Year Book, Inc; 1988:149-55.
Strom TB, Tilney NL. Immunobiology and immunopharmacology of graft rejection. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 5th ed. Boston: Little, Brown and Company; 1993: 2879-910.
Kimberly RP. Pulse methylprednisolone in SLE. Clin Rheum Dis. 1982; 8:261-78.
Liebling MR, Leib E, McLaughlin K, Blocka K, Furst DE, Nyman K, et al. Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial. Ann Intern Med. 1981; 94:21-6.
Neustadt DH. Systemic corticosteroids. In: Katz WA; ed. The Diagnosis and Management of Rheumatic Diseases. 2nd ed. Philadelphia: JB Lippincott; 1988:805-11.
Boumpas DT, Austin HA, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992; 340:741-5.
Baxter JD. Minimizing the side effects of glucocorticoid therapy. Adv Intern Med. 1990; 35:173-94.
Dale DC, Petersdorf RG. Corticosteroids and infectious diseases. Med Clin North Am. 1973; 57:1277-87.
Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989; 11:954-63.
Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991; 114:735-40.
Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med. 1986; 80:925-9.
Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992; 93:513-9.
Ettinger WH, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism. 1988; 37:1055-8.
Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990; 112:352-64.
Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med. 1990; 150:2545-8.
Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983; 309:265-8.
Riggs BL, Melton III LJ. The prevention and treatment of osteoporosis. N Engl J Med. 1992; 327:620-7.
Villareal DT, Civitelli R, Gennari C, Avioli LV. Is there an effective treatment for glucocorticoid-induced osteoporosis? Calcif Tissue Int. 1991; 497:141-2.
Silverman SL. Management of corticosteroid-induced osteoporosis: a clinician's perspective. Calcif Tissue Int. 1992; 50:101-3.
Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation of bone loss in postmenopausal women. N Engl J Med. 1993; 328:460-6.
Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Pharmacol. 1987; 33:35-9.
Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosponate (APD). Lancet. 1988; 1:143-6.
Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med. 1992; 326:1473-9.
Zizic TM. Osteonecrosis. Curr Opin Rheumatol. 1991; 3:481-9.
Scudeletti M, Castagnetta L, Imbimbo B, Puppo F, Pierri I, Indiveri F. New glucocorticoids. Ann N Y Acad Sci. 1990; 595:368-82.
Kimberly RP. Glucocorticoid therapy for rheumatic diseases. Curr Opin Rheumatol. 1992; 4:325-31.
Gray RE, Doherty SM, Galloway J, Coulton L, de Broe M, Kanis JA. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum. 1991; 34:287-
Paliogianni F, Valentine MA, Boumpas DT. Glucocorticoids (GC) inhibit calcium (Ca2+) but not protein kinase C (PKC)-dependent pathways for T-cell activation. Arthritis Rheum. 1993; 36:5113.
Sambrook P, Birmingham RN, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis. N Engl J Med. 1993; 328:1747-52.
Meunier PJ. Is steroid-induced osteoporosis preventable? N Engl J Med. 1993; 328:1781.